With ADAP’s Phase II trial announcement approaching, volatility could rise. Market models suggest a scenario where favorable data lifts stock value by 20%. Traders should monitor options activity for clues. With a stake of 6.7%, private equity firms could influence the Adaptimmune Therapeutics board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public. Adaptimmune Therapeutics ( (ADAP) ) has shared an announcement. ADAP’s long-term growth forecast hinges on expanding its immunotherapy portfolio. Analysts maintain a speculative buy rating based on anticipated revenue streams post-